Patent · US Active

Fc variants with altered binding to FcRn

US8088376B2 · kind B2 · utility

72Cited by

3References

1Claims

0Family size

Assignee

Xencor, Inc. · US

Inventors

Aaron Keith Chamberlain · San Diego, US
Bassil Dahiyat · Altadena, US
John Desjarlais · Pasadena, US
Sher Bahadur Karki · Pasadena, US
Gregory Alan Lazar · Los Angeles, US

Key dates

Filing date	Jan 18, 2011
Grant date	Jan 3, 2012
Priority date	—
Expiry date	Jan 18, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.